Tiziana Life Sciences Ltd (TLSA) Financial Ratios
27 years of historical data (1998–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
19.38
↑+414% vs avg
5yr avg: 3.77
30Y Low1.1·High9.4
ROE
↓
-250.5%
↑-117% vs avg
5yr avg: -115.4%
30Y Low-430%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TLSA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tiziana Life Sciences Ltd currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $182M | $37M | $28M | $30M | $47M | $98M | $184M | $254M | — | — | — |
| Enterprise Value | $178M | $34M | $27M | $13M | $5M | $33M | $185M | $250M | — | — | — |
| P/E Ratio → | -6.50 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 19.38 | 9.43 | 5.14 | 1.56 | 1.14 | 1.58 | — | 620.62 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TLSA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TLSA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -250.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -250.5% | -250.5% | -140.9% | -50.6% | -45.2% | -89.8% | — | -1540.1% | -830.2% | -122.0% | -167.9% |
| ROA | -101.1% | -101.1% | -91.5% | -40.9% | -39.2% | -72.1% | -201.2% | -172.9% | -196.7% | -100.8% | -147.4% |
| ROIC | -481.7% | -481.7% | -420.6% | -966.8% | -4572.5% | — | — | — | — | — | — |
| ROCE | -329.7% | -329.7% | -141.3% | -47.7% | -52.7% | -95.2% | — | -1912.9% | -1011.2% | -123.3% | -167.6% |
TLSA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $106000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.02 | 0.03 | 0.01 | — | 0.60 | — | 0.07 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.92 | -0.17 | -0.91 | -1.02 | -1.05 | — | -9.62 | — | -1.35 | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2632.33 | -2632.33 | -1798.40 | -2083.71 | -155.53 | -87.58 | -106.48 | -827.33 | -916.22 | -809.78 | -478.56 |
Net cash position: cash ($4M) exceeds total debt ($106000)
TLSA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.02x means Tiziana Life Sciences Ltd can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.64x to 1.02x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | 1.02 | 1.12 | 3.64 | 6.45 | 8.79 | 0.21 | 1.08 | 0.52 | 2.89 | 12.40 |
| Quick Ratio | 1.02 | 1.02 | 1.12 | 3.64 | 6.45 | 8.79 | 0.21 | 1.08 | 0.52 | 2.89 | 12.40 |
| Cash Ratio | 0.51 | 0.51 | 0.18 | 2.72 | 5.59 | 8.25 | 0.03 | 0.83 | 0.01 | 2.71 | 11.93 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.29 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
TLSA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tiziana Life Sciences Ltd does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $53M | $51M | $51M | $49M | $49M | $68M | $68M | $58M | $53M | $47M |
Peer Comparison
Compare TLSA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TLSAYou | $182M | -6.5 | — | — | — | — | -250.5% | -481.7% | — |
 IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
 ARCT | $239M | -3.5 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 PRAX | $8B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 INVA | $2B | 6.9 | 5.6 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
 AGIO | $2B | -3.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 FATE | $272M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.6 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 ADMA | $2B | 12.7 | 16.5 | 22.2 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
See TLSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TLSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TLSA vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonTLSA — Frequently Asked Questions
Quick answers to the most common questions about buying TLSA stock.
What is Tiziana Life Sciences Ltd's P/E ratio?
Tiziana Life Sciences Ltd's current P/E ratio is -6.5x. This places it at the 50th percentile of its historical range.
What is Tiziana Life Sciences Ltd's ROE?
Tiziana Life Sciences Ltd's return on equity (ROE) is -250.5%. The historical average is -125.6%.
Is TLSA stock overvalued?
Based on historical data, Tiziana Life Sciences Ltd is trading at a P/E of -6.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.